The verdict
Our read at a glance.
Whether terlipressin's approved hepatorenal syndrome use is understood within that specific, serious indication and its risk profile, rather than generalized.
- The signal
- Randomized trials, including the CONFIRM trial, support terlipressin for improving kidney function in hepatorenal syndrome, though the benefit comes with notable risks. It also has a long international track record in variceal bleeding.
- The unknown
- How to weigh its kidney benefit against serious risks such as respiratory failure, and which patients are most likely to benefit safely.
- Our read
- A serious hospital drug for a life-threatening condition, with real benefit and real risk. Terlipressin can improve kidney function in hepatorenal syndrome, but its respiratory and ischemic warnings mean it belongs only in that specific, supervised setting.
The mechanism
How it works.
Terlipressin is a synthetic analog of vasopressin (a prodrug slowly converted to lysine-vasopressin in the body) that activates V1 receptors on smooth muscle in blood vessels, making them constrict. It works mainly in the splanchnic circulation supplying the gut, and squeezing those vessels raises blood pressure in the rest of the body so more blood reaches the kidneys in hepatorenal syndrome. In variceal bleeding, the same constriction cuts blood flow and pressure in the dilated veins that are bleeding.
Safety & regulatory boundary
The consequential part.
Terlipressin carries a boxed warning for serious or fatal respiratory failure and is not recommended in patients with certain levels of kidney dysfunction or in advanced acute-on-chronic liver failure, and it can cause ischemic events. It is a hospital-administered drug for a specific serious indication. Terlivaz and other terlipressin products are not the same as compounded or research-labeled terlipressin, and the approved use does not extend to any general or wellness setting.
What's next
What we're watching.
Real-world safety in hepatorenal syndrome, patient-selection refinements, and comparative data with other vasoconstrictor strategies.
Context
Why this is discussed.
Terlipressin addresses hepatorenal syndrome, a life-threatening kidney complication of advanced liver disease, where options are limited.
The evidence base
21 cited references.
Regulatory & labels1
Mallinckrodt Hospital Products Inc. (FDA label) · 2025
Registered trials8
ClinicalTrials.gov · NA · RECRUITING · 2025-03-06
ClinicalTrials.gov · NA · RECRUITING · 2025-12-29
ClinicalTrials.gov · PHASE3 · COMPLETED · 2022-03-27
ClinicalTrials.gov · PHASE2 · ACTIVE_NOT_RECRUITING · 2024-04-17
ClinicalTrials.gov · NA · NOT_YET_RECRUITING · 2026-05-10
ClinicalTrials.gov · NA · COMPLETED · 2025-05-01
ClinicalTrials.gov · PHASE3 · NOT_YET_RECRUITING · 2026-03-01
ClinicalTrials.gov · PHASE3 · COMPLETED · 2017-06-30
Indexed literature (PubMed)12
Tapper EB et al. · JAMA · 2023
Russell JA · Intensive Care Med · 2019
Pose E et al. · Gastroenterology · 2024
Khemichian S et al. · Annu Rev Med · 2025
Avni T et al. · PLoS One · 2015
Belletti A et al. · J Cardiothorac Vasc Anesth · 2021
Huaringa-Marcelo J et al. · J Gastrointestin Liver Dis · 2021
Wong F et al. · N Engl J Med · 2021
Kotani Y et al. · Crit Care · 2024
Jia L et al. · Shock · 2023
Belcher JM · Med Clin North Am · 2023
Francoz C et al. · Clin J Am Soc Nephrol · 2019
Keep reading